UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June 27~~August 6, 2019

Dova Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)




Delaware (State or Other Jurisdiction of Incorporation)	001-38135 (Commission File Number)	81-3858961 (IRS Employer Identification No.)

240 Leigh Farm Road, Suite 245 Durham, North Carolina (Address of Principal Executive Offices) 27707 (Zip Code)

Registrant’s telephone number, including area code: (919) 748-5975

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the ~~Securities Exchange~~ Act ~~of 1934~~:

Title of each class ~~Tradingsymbol~~Trading symbol(s) Name of each ~~exchangeon~~exchange on which registered Common Stock DOVA The Nasdaq Stock Market, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒ý

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ý

Item 12.~~01 Entry~~02 Results ~~into~~of aOperations ~~Material~~and ~~Definitive~~Financial ~~Agreement~~Condition.

On ~~June 27~~August 6, 2019, Dova Pharmaceuticals, Inc. (the “Company”) ~~and~~issued ~~Bausch~~a ~~Health~~press ~~US,~~release ~~LLC,~~announcing ~~formerly~~its ~~known~~financial asresults ~~Valeant~~for ~~Pharmaceuticals North America LLC (”Bausch Health”) entered into a First Amendment to~~ the ~~Co-Promotion~~quarter ~~Agreement~~ended ~~effective July 1~~June 30, 2019, ~~(the~~as ~~“Amendment”)~~well inas ~~which~~information ~~the~~regarding ~~Company~~a ~~and~~conference ~~Bausch~~call ~~Health agreed~~ to ~~amend~~discuss ~~certain~~these ~~terms~~financial ofresults ~~the Co-Promotion Agreement by~~ and ~~between~~ the Company’s ~~and~~recent ~~Bausch~~corporate ~~Health,~~highlights ~~dated~~and ~~September 26, 2018 (the “Agreement”)~~outlook. ~~Pursuant~~ toThis ~~the~~press ~~Agreement,~~release ~~the~~has ~~Company~~been ~~granted~~furnished ~~Bausch~~as ~~Health~~Exhibit ~~the exclusive right to co-promote DOPTELET (avatrombopag) to specified medical professionals in the Gastroenterology, Colorectal Surgery and Proctology field (the “Specialty”) in the United States~~99.1 ~~Pursuant~~ to ~~the~~this ~~Amendment,~~Current ~~the~~Report ~~Company~~on ~~expanded~~Form ~~its partnership with Bausch Health, whereby Bausch Health will now have the exclusive right to also co~~8-~~promote~~K ~~in Hepatology,~~ and ~~Interventional~~is ~~Radiology,~~incorporated inherein ~~addition~~by to the previously defined Specialty (collectively, the “Expanded Specialty”) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedurereference.

~~Under~~The ~~the~~information ~~Amendment,~~in ~~the~~this ~~Company~~Current ~~will~~Report ~~continue to pay Bausch Health a fee based~~ on ~~the~~Form ~~quarterly~~8-K, ~~Net~~including ~~Sales~~Exhibit ~~(as~~99.1 ~~defined~~attached ~~in the Amendment) of DOPTELET to specified medical professionals in the Expanded Specialty in the United States~~hereto, ~~which,~~is ~~commencing~~being onfurnished ~~July~~and 1,shall ~~2019,~~not ~~will~~be ~~equal~~deemed a“filed” ~~mid-thirties~~for ~~percentage~~purposes of ~~those~~Section ~~Net~~18 ~~Sales~~of inthe aSecurities ~~calendar~~Exchange ~~year. Pursuant~~Act toof ~~the Amendment~~1934, ~~the~~as ~~Company~~amended ~~agreed to extend~~ (the ~~term~~“Exchange ofAct”) ~~the~~or ~~Agreement~~otherwise bysubject anto ~~additional year until~~ the ~~five~~liabilities ~~year anniversary~~ of ~~the~~that ~~original agreement date~~section. ~~Subject~~The toinformation ~~early~~contained ~~termination,~~herein ~~the~~and ~~amended~~in ~~term of~~ the ~~Agreement~~accompanying ~~now~~exhibit ~~expires~~is onnot ~~September~~incorporated ~~26,~~by ~~2023.~~reference ~~Under~~in ~~the~~any ~~terms~~filing of the ~~Amendment, the~~ Company ~~remains~~under ~~responsible for~~ the ~~costs~~Securities ofAct ~~maintaining regulatory approval~~ of, ~~manufacturing~~1933, ~~supplying~~as ~~and~~amended, ~~distributing~~or ~~DOPTELET.~~the ~~Bausch~~Exchange ~~Health~~Act, ~~will~~whether ~~continue~~made tobefore ~~maintain~~or atafter ~~least~~the ~~one~~date ~~hundred~~hereof ~~(100)~~and ~~sales~~irrespective ~~representatives~~of ~~(subject~~any togeneral ~~certain~~incorporation ~~adjustments)~~language ~~that will have the responsibility to promote DOPTELET~~ in ~~the~~any ~~Expanded Specialty in the United States~~filings.

The foregoing is a summary description of certain terms of the Amendment, is not complete and is qualified in its entirety by reference to the text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01 Other Events.

On June 27, 2019, the Company announced that the U.S. Food and Drug Administration approved a supplemental New Drug Application that expands the use of DOPTELET (avatrombopag) to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K, the contents of which are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
Exhibit
10.1*		First Amendment to the Co-Promotion Agreement, dated June 27, 2019.
Number		Exhibit Description
99.1		Press ~~release~~Release, dated ~~June~~August 276, 2019.
* Portions of this exhibit (indicated by asterisks) have been excluded because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Dova Pharmaceuticals, Inc.
Date: June 27, 2019	/s/ Mark W. Hahn
	Mark W. Hahn
	Chief Financial Officer

Dova Pharmaceuticals, Inc.



Date: August 6, 2019	/s/ Mark W. Hahn
	Mark W. Hahn
	Chief Financial Officer

Filing Compare · Dova Pharmaceuticals Inc.